Last Updated: September 24, 2026

Details for Patent: 6,251,910

Name: Drug Patent Intelligence for US Patent 6251910
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,251,910

Title:	1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Abstract:	Compounds of formula having the following stereochemistry wherein R, R1, R2, R3 and R4 are as defined in the specification. The compounds are useful as P2T receptor antagonists.
Inventor(s):	Simon Guile, Anthony Ingall, Brian Springthorpe, Paul Willis
Assignee:	AstraZeneca UK Ltd
Application Number:	US09/155,023
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,251,910
Patent Claim Types: see list of patent claims	Use; Composition; Process;

Drugs Protected by US Patent 6,251,910

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 6,251,910

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	9702773	Jul 22, 1997

PCT Information
PCT Filed	July 15, 1998	PCT Application Number:	PCT/SE98/01393
PCT Publication Date:	February 04, 1999	PCT Publication Number:	WO99/05143

International Family Members for US Patent 6,251,910

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	017014	⤷ Start Trial
Argentina	077553	⤷ Start Trial
Austria	251161	⤷ Start Trial
Australia	745381	⤷ Start Trial
Australia	8370698	⤷ Start Trial
Brazil	9810802	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.